These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2086491)

  • 1. N-acetylation and debrisoquine type oxidation polymorphism in Caucasians--with reference to age and sex.
    Siegmund W; Hanke W; Zschiesche M; Franke G; Biebler KE; Wilke A
    Int J Clin Pharmacol Ther Toxicol; 1990 Dec; 28(12):504-9. PubMed ID: 2086491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Debrisoquine oxidation in an Australian population.
    Peart GF; Boutagy J; Shenfield GM
    Br J Clin Pharmacol; 1986 May; 21(5):465-71. PubMed ID: 3718805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debrisoquine hydroxylation and sulfamethazine acetylation in a Chinese population.
    Xu XM; Jiang WD
    Zhongguo Yao Li Xue Bao; 1990 Sep; 11(5):385-8. PubMed ID: 2130590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome.
    Siegmund W; Fengler JD; Franke G; Zschiesche M; Eike O; Eike E; Meisel P; Wulkow R
    Br J Clin Pharmacol; 1991 Oct; 32(4):467-72. PubMed ID: 1958441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Genetic polymorphism in Gilbert-Meulengracht syndrome (GMS)].
    Fengler JD; Baumgarten R; Eike E; Eike O; Siegmund W; Franke G; Zschiesche M
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():81-2. PubMed ID: 7483725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.
    Graf T; Broly F; Hoffmann F; Probst M; Meyer UA; Howald H
    Eur J Clin Pharmacol; 1992; 43(4):399-403. PubMed ID: 1451720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Debrisoquine oxidation phenotype during neuroleptic monotherapy.
    Spina E; Martines C; Caputi AP; Cobaleda J; Piñas B; Carrillo JA; Benitez J
    Eur J Clin Pharmacol; 1991; 41(5):467-70. PubMed ID: 1684751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for the polymorphic oxidation of debrisoquine and proguanil in a New Zealand Maori population.
    Wanwimolruk S; Pratt EL; Denton JR; Chalcroft SC; Barron PA; Broughton JR
    Pharmacogenetics; 1995 Aug; 5(4):193-8. PubMed ID: 8528265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Debrisoquine oxidation polymorphism in a Tasmanian population.
    Veronese ME; McLean S
    Eur J Clin Pharmacol; 1991; 40(5):529-32. PubMed ID: 1884730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Debrisoquine and N-acetylation polymorphism in Syria.
    Roustom R; Siegmund W; Zschiesche M; Franke G
    Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):543-4. PubMed ID: 1490826
    [No Abstract]   [Full Text] [Related]  

  • 13. Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients.
    Spina E; Campo GM; Calandra S; Caputi AP; Carrillo JA; Benitez J
    Pharmacol Res; 1992 Jan; 25(1):43-50. PubMed ID: 1738757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with Parkinson's disease].
    Milejski P; Orzechowska-Juzwenko K; Kamienowski J; Horoch E; Niewiński P; Hurkacz M; Rzemisławska Z
    Neurol Neurochir Pol; 1999; 33(5):1015-24. PubMed ID: 10672554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism of debrisoquine oxidation in New Zealand Caucasians.
    Wanwimolruk S; Denton JR; Ferry DG; Beasley M; Broughton JR
    Eur J Clin Pharmacol; 1992; 42(3):349-50. PubMed ID: 1577057
    [No Abstract]   [Full Text] [Related]  

  • 17. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
    Wanwimolruk S; Patamasucon P; Lee EJ
    Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic oxidation of debrisoquine in bladder cancer.
    Benítez J; Ladero JM; Fernández-Gundín MJ; Llerena A; Cobaleda J; Martínez C; Muñoz JJ; Vargas E; Prados J; González-Rozas F
    Ann Med; 1990 Jun; 22(3):157-60. PubMed ID: 2393550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
    Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.